

XOFLX[®] Lentiviral Packaging & Producer Cell Lines for Scalable, Cost-Efficient LVV Manufacturing



Flyer

Minaris Advanced Therapies is a global leader in cell and gene therapy manufacturing, supporting innovators from development through commercialization. Lentiviral vectors remain a powerful workhorse for both ex vivo and in vivo gene therapies, yet translating early research strategies into consistent, large-scale, and market-ready solutions remains a critical industry challenge.

XOFLX[®] is Minaris' Lentiviral Packaging & Producer Cell Line platform, designed to strengthen and streamline LVV production while reducing manufacturing costs. By enabling a more efficient and scalable manufacturing foundation, XOFLX[®] helps developers move beyond concept toward sustainable, broad patient access.

Why Stable Cell Lines Are Key to Scalable LVV Manufacturing

Reduce COGs by minimizing or eliminating plasmid requirements



De-risk manufacturing by simplifying or removing transfection



Enable scalable production, including feasibility beyond 1000L (producer)



Accelerate market adoption with established master cell banks (packaging) and developed processes

XOFLX[®] At a Glance

- Stable cell lines**
with genomically integrated LV components
- Lower LVV cost of goods (COGs)**
through reduced plasmid costs and improved scale
- Reduced plasmid or plasmid-free production**
for better raw material control
- Large-volume production (>1000L)**
in scalable producer formats
- Transfection simplified or eliminated**
to reduce variability and process risk
- Established Master Cell Banks**
of packaging cell line to support reliable long-term supply
- Commercial-ready**
manufacturing processes developed for market readiness
- Applicable to ex vivo and in vivo therapies**
using lentiviral vectors


Transient Transfection vs XOFLX®

	Transient Transfection	XOFLX® Platform
Production Method	Requires 4 plasmids per batch	Single plasmid transfection in Packaging lines; no plasmids needed for producer lines. Custom producer cell lines are plasmid-free
Yield Consistency	10 ⁶ -10 ⁷ TU/mL, ±50% variability	Comparable/ higher titers than 4-plasmid production; reduced batch-to-batch variability
Scalability	Challenging above 50-200L	The producer cell line has potential for >1000 L production
Cost of Goods	\$1M-2M per GMP batch	Lower, due to reduced plasmid requirement and greater efficiency
Timeline	6-9 month optimization cycles	Faster path due to the lower complexity of the production

Custom XOFLX® Cell Line Development Services

Minaris offers tailored programs to create packaging or producer lines that meet client-specific therapeutic needs.

Project timelines are structured to accelerate progress from early development to LVV GMP manufacturing, derisking commercialization.



Stable integration of packaging components, including therapeutic-specific envelop gene



Stable integration of therapeutic transgenes



Clone selection and productivity screening



Assay development to evaluate potency, residuals and safety



Transition from preclinical banks to GMP-compliant Master Cell Banks



CONTACT US

Get in Touch With Our Team Today

minaris.com/contact

